ASCENTAGE PHARMA GROUP INTERNATIONAL

Ascentage Pharma announced multiple clinical and preclinical data presentations at the 68th ASH Annual Meeting. Key highlights include oral presentation of APG-5918 Phase 1 data in R/R TCL showing promising efficacy, and poster presentations detailing combination therapies for various hematologic malignancies including olverembatinib and lisaftoclax. The company also presented preclinical findings on APG-5918 and lisaftoclax in DLBCL models.

Ascentage Pharma Group International announced on October 15, 2026, that its trustee purchased 200,000 existing shares on the open market for the 2022 RSU Scheme. The total cost for these shares was HK$5,778,916, averaging HK$28.89 per share, which represents approximately 0.05% of the company's total issued shares. This transaction brings the total shares held by the trustee for the scheme to 2,915,000.

Ascentage Pharma Group International announced it will release its 2026 six-month unaudited interim results and provide business updates on August 19, 2026, with an investor webcast scheduled for 7:00 am EDT. The company also corrected the timing for its English language investor conference call to August 20, 2026, at 8:00 am EDT. Additionally, Ascentage Pharma management will participate in the Evercore 2nd Annual China Biotech Summit from August 17-19, 2026, including a fireside chat and one-on-one investor meetings.

Ascentage Pharma Group International announced that its Board of Directors will hold a meeting on August 19, 2026. The primary agenda for this meeting is to consider and, if deemed appropriate, approve the unaudited interim financial results for the six months that concluded on June 30, 2026, and to authorize their publication.

Ascentage Pharma Group International announced it will release its six months 2026 unaudited interim results and provide business updates on August 19, 2026, at 7:00 am Eastern Daylight Time (EDT) / 7:00 pm Hong Kong Time (HKT). The company will host investor webcasts with Q&A sessions. A Chinese (Mandarin) language webcast is scheduled for August 19, 2026, at 9:00 pm EDT, and an English language webcast for August 20, 2026, at 8:00 am EDT.

Ascentage Pharma Group International announced it will release its six months 2026 unaudited interim results and provide business updates on August 19, 2026. The company will host an investor webcast with Q&A on the same day at 9:00 am EDT. Additionally, Chinese and English language investor conference calls and webcasts are scheduled for August 19 and August 20, 2026, respectively, to discuss the results.

Ascentage Pharma Group International announced the appointment of Dr. Faiçal Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer. These strategic hires aim to strengthen the company's global business development and establish a dedicated US commercialization function. Both executives bring extensive experience in the biopharmaceutical industry and will report to the Chairman and CEO, Dr. Dajun Yang, as the company enters a new phase of global expansion.

Ascentage Pharma Group International has announced two key executive appointments to bolster its global expansion. Dr. Faiçal Miyara has been named Chief Business Officer, responsible for global business development, while Jim Ziegler has been appointed Chief Commercial Officer, overseeing commercialization in the US and other markets outside China. Both will report to the CEO and bring extensive experience to strengthen the company's capabilities as it advances multiple global registrational Phase III studies.

Ascentage Pharma announced that its Chairman and CEO, Dr. Dajun Yang, has been named to The Medicine Maker Power List 2026, ranking No. 3 in the Small Molecules category. This recognition highlights his over 30 years of work in oncology and innovative drug development, leading Ascentage Pharma to commercialize two therapies, olverembatinib and lisaftoclax, and advance multiple global Phase III clinical studies. The company also achieved dual primary listings under his leadership.

Ascentage Pharma Group International announced a proposed At-The-Market (ATM) offering program to sell up to $200 million of its American Depositary Shares (ADSs). The company filed an automatic shelf registration statement on Form F-3 with the U.S. SEC for this purpose. The net proceeds are intended to fund the commercialization of its drug candidates Olverembatinib and Lisaftoclax, support ongoing clinical trials, and cover working capital and general corporate purposes. The program is subject to obtaining waivers from the Hong Kong Listing Rules, and sales will be conducted on Nasdaq through designated sales agents.